Gränslös Innovation

Cristina GladSkånska Utvecklingsdagen

14 november 2005

Presentationen har inför publicering på skane.se rensats på bildelement pga utrymmesskäl.

14 samverkande Universitet26 sjukhus varav 11 universitetssjukhus

Acumulated total of new biotech companies (excluding medical technology and CROs)

0

20

40

60

80

100

120

140

160

1997 1998 1999 2000 2001 2002 2003 2004

New

Total

Total no of start-ups: 110 Still existing 2005: 95Companies closed: 10Mergers/Acquisitions: 5

Medicon Valley

Blockbusters

Cipramil (antidepressive)

Lundbeck

NovoPen (insulin)

Novo Nordisk

Turbuhaler (powder inhalator)

AstraZeneca, Lund

Umeå Uppsala - Stockholm - Str-näs Linköping Gothenburg Others Malmö/Lund Copenhagen

Medicon Valley

Swedish regions and Copenhagen - companies with an international market, excl. sales

K96-LU470K108-LU5600

K91-LU97

K92-LU50

K132-MT278K140-MT380

K81-LP55

K72-LP320

K76-LP/LU380

K10-BP1231

Pro

duct

de

velo

pmen

t

Wid

e-ra

nge

rese

arch

& d

evel

opm

ent

Pro

duct

ion

Nar

row

rese

arch

&

dev

elop

men

t C

onsu

ltanc

y

with

out -

w

ith -

with

out -

w

ith p

rodu

ct

Red=pharma; Pink= CRO; Yellow=medtech; Blue=biotech foodsViolet=pharma production (only); Brown=biotech/bioproduction

Source: Critical I Limited

The European biotech landscape

Bioteknikbolagen I Europa är många men har svårt att växa

Source: Critical I Limited

0

20

40

60

80

0-2 y 3-5 y 6-10 y 11-15 y

Empl

oyee

sEurope USA

”At the point at which Europe’s companies ought to be taking off, most of them appear to run out of financial runway”

0.0

2.0

4.0

6.0

8.0

10.0

12.0

Sverige Danmark

Intäkter m€

0

5

10

15

20

25

30

35

40

45

50

Sverige Danmark

Antal anstälda

0 - 2 år3 - 5 år6 - 10 år11 - 15 år

Getting venture investment in European biotechnology depends on being in the right place

Source: Critical I Limited

Capital to Biotech (Nov 2004-July 2005)BioEtt (Nov-04) 0.6Celltrix (Nov-04) 1Symphogen (Nov-04) 21Probi (IPO) (Dec-04) 4CMC (Jan-05) 14Ultrazonix (Jan-05) 3Zealand Pharma (Feb-05) 26LiPlasome (Mar-05) 6SpectraCure (Mar-05) 2TopoTarget (Mar-05) 15Evolva (Mar-05) 14Mitra Medical (Mar-05) 3 Acadia (Apr-05) 30NsGene (May-05) 4LifeCyclePharma (May-05) 15Exiqon (May-05) 17Pharmexa (publ.) (Jun-05) 40ProstaLund (Jun-05) 3TopoTarget (IPO) (Jul-05) 31Medtentia (Jul-05) 1Active Biotech (Jul-05) 18TOTAL 60 >200 M€

Medicon Valley Academy

Initiative 1995 from universities and big pharma companies

2000: Private membership basednon profit organisation Universities, hospitals &companies (260 members)

2 nations – 2 systems

Innovation Potential in Medicon Valley

Research

Technology Transfer

Companies

From BioScience to New Jobs in Medicon Valley - A Medicon Valley Academy Strategic Report

300 million € university research3200 publications/yr>150 inventions/yr

400 bio-companies40,000 employees

1) More commercial know-how into Technology Transfer Organisations

2) Regional TTO cooperation (!)

3) Funding for Proof - of- Concept studies

4) Seed investments across Øresund (!)

5) Tax incentives for the Young Biotech Industry

From BioScience to New Jobs in Medicon Valley - A Medicon Valley Academy Strategic Report

Innovation Report 2004Recommendations to improve the competitiveness of Medicon Valley

Våra Svagheter

• Svårt att växa• Brist på kapital • Kompetens inom utveckling och

kommersialisering• Svårt attrahera utländsk arbetskraft• Skatter och avgifter • Hjälpande infrastruktur

Vi måste vara attraktiva

Våra Styrkor

• Tillgång på högutbildad personal• Tillgång på kompetens från andra företag• Samarbete med akademin• Innovationsklimatet inom akademin

– Lärarundantaget– Holdingbolag, Innovationsbron etc.

•BMC (Lund)

Bio Medical Center

•CRC (Malmö)

Clinical Research Center

•BRIC (Copenhagen)

Biotech Research and Innovation Center

Total investments 0.3-0.4 billion €

• SWEGENE (Lund)Postgenomic RT Programme in South Western Sweden

Research infrastructure investments

Proteomics

Microarray

Cryo-EM

Genomic EcologyUniversity Hospital

BMC

IdeonSciencePark

MAX-lab

Transgenic core facility

Bioinformatics

Chemical Centre

LTH

Sony Ericsson

Gambro

Active Biotech

Astra Zeneca

500 m

School of Economics

LUND North Campus AreaESS?